Key facts
- Notable investors include Life Sciences BC, Amplitude Ventures, Novateur Ventures, Repare Therapeutics.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for DCx Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for DCx Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DCx Biotherapeutics
Developer of precision oncology therapeutics intended to revolutionize patient outcomes against genetically defined cancers. The company's platform, named music, integrates high-throughput functional screening, deep bioinformatics, and machine learning to identify synergistic intracellular and cell-surface targets and is focused on developing multi-modal antibody drug conjugates (MM-ADCs), enabling the biotechnology sector to access a new class of multi-modal, synergistic-targeting treatments with improved efficacy and tolerability against a range of tumor types.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2025
- Employees
- 26
- Website
- dcxbio.com/
- Ownership
- Privately Held (backing)
DCx Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DCx Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DCx Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.